Registration No: 201501009903 (1135238-U)

(Incorporated in Malaysia)

INTERIM FINANCIAL REPORT FOR THE FOURTH (4th) QUARTER ENDED 31 DECEMBER 2021

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME (1)

(The figures have not been audited)

	Note	Individual Quarter (Unaudited) (Unaudited) 31-Dec-21 31-Dec-20 RM'000 RM'000		Cumulativ (Unaudited) 31-Dec-21 RM'000	e Quarter (Audited) 31-Dec-20 RM'000
	Hote	KM 000	KM 000	KM 000	KM 000
Revenue	A7	25,553	15,702	75,259	68,127
Cost of Sales		(15,403)	(9,841)	(45,299)	(43,932)
Gross Profit	-	10,150	5,861	29,960	24,195
Other operating income		3,192	296	2,737	1,133
Administrative expenses		(10,020)	(5,506)	(29,885)	(20,321)
Profit from operations	-	3,322	651	2,812	5,007
Finance costs		(138)	(212)	(556)	(394)
Profit before taxation	A7	3,184	439	2,256	4,613
Taxation	B5	(702)	(142)	(2,158)	(1,297)
Profit for the financial period	_	2,482	297	98	3,316
Other comprehensive income/(loss), net of tax Revaluation surplus on properties Tax effect on items that will not be reclassified to profit or loss Total comprehensive income Profit/(Loss) for the financial period attributable to: Owners of the Company Non-controlling interests Total comprehensive income/(loss) attributable to:	-	(511) (511) 1,971 2,611 (129) 2,482	297 285 12 297	5,109 (511) 4,598 4,696 (1,176) 1,274 98	2,658 658 3,316
Owners of the Company		2,100	285	3,422	2,658
Non-controlling interests	-	(129)	12	1,274	658
	-	1,971	297	4,696	3,316
Weighted average number of ordinary shares in issue ('000)	B10	1,564,702	434,991	914,532	424,704
Earnings/(Loss) per share attributable to owners of the Company (sen): -Basic ⁽²⁾ /Diluted ⁽³⁾	B10	0.17	0.07	(0.13)	0.63

Registration No: 201501009903 (1135238-U)

(Incorporated in Malaysia)

INTERIM FINANCIAL REPORT FOR THE FOURTH (4th) QUARTER ENDED 31 DECEMBER 2021

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME (Continued) (1)

(The figures have not been audited)

Notes:

- (1) The Unaudited Condensed Consolidated Statement of Comprehensive Income should be read in conjunction with the audited financial statements of the Group for the financial year ended ("FYE") 31 December 2020 as well as the accompanying explanatory notes attached to this interim financial report.
- (2) Basic earnings/(loss) per share is calculated based on the weighted average number of ordinary shares in issue.
- (3) Diluted earnings/(loss) per share of the Group is equivalent to the basic earnings/(loss) per share as the effects on the assumed exercise of the share options under warrants is anti-dilutive.

Registration No: 201501009903 (1135238-U)

(Incorporated in Malaysia)

INTERIM FINANCIAL REPORT FOR THE FOURTH (4th) QUARTER ENDED 31 DECEMBER 2021

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION (1)

(The figures have not been audited)

ASSETS	Note	(Unaudited) As at 31 December 2021 RM'000	(Audited) As at 31 December 2020 ⁽²⁾ RM'000
NON-CURRENT ASSETS			
Property, plant and equipment		17,944	11,369
Right-of-use assets		2,021	2,614
Investment properties		5,501	601
Intangible assets		19,024	-
Goodwill		1,332	-
Investment in quoted shares		26,336	-
		72,158	14,584
CURRENT ACCETS			
CURRENT ASSETS Inventories		25,968	14,356
Trade receivables		18,767	15,227
Other receivables, prepayments and deposits		39,610	2,109
Tax recoverable		1,173	894
Fixed deposits with licensed banks		39,686	1,815
Cash and bank balances		25,935	45,756
TOTAL CURRENT ASSETS		151,139	80,157
TOTAL ASSETS		223,297	94,741
EQUITY AND LIABILITIES EQUITY Share capital Merger reserves Revaluation reserves Warrant reserve Other reserve Retained earnings Equity attributable to owners of the Company Non-controlling interests TOTAL EQUITY		153,570 (16,049) 4,598 29,004 (29,004) 35,892 178,011 4,599 182,610	47,356 (16,049) - - - 37,068 68,375 3,085 71,460
CURRENT LIABILITIES Contract liabilities		358	473
Trade payables		17,481	5,201
Other payables and accruals		8,293	8,879
Amout due to directors		247	-
Lease liabilities	В7	1,082	1,036
Bank borrowings	В7	4,149	3,346
Tax payable		140	35
TOTAL CURRENT LIABILITIES		31,750	18,970

Registration No: 201501009903 (1135238-U)

(Incorporated in Malaysia)

INTERIM FINANCIAL REPORT FOR THE FOURTH (4th) QUARTER ENDED 31 DECEMBER 2021

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION (Continued) $^{(1)}$

(The figures have not been audited)

	Note	(Unaudited) As at 31 December 2021 RM'000	(Audited) As at 31 December 2020 (2) RM'000
NON-CURRENT LIABILITIES	_		
Lease liabilities	В7	1,513	1,882
Bank borrowings	В7	6,729	2,324
Deferred tax liabilities		695	105
TOTAL NON-CURRENT LIABILITIES	•	8,937	4,311
TOTAL LIABILITIES		40,687	23,281
TOTAL EQUITY AND LIABILITIES	·	223,297	94,741
(200) (3)			
Net assets per share (RM) (3)		0.11	0.14

Notes:

- (1) The Unaudited Condensed Consolidated Statement of Financial Position should be read in conjunction with the audited financial statements of the Group for the FYE 31 December 2020 as well as the accompanying explanatory notes attached to this interim financial report.
- (2) The summary of the statement of financial position prepared based on the audited financial statement of the Group as at 31 December 2020.
- (3) Net assets per share is calculated based on the number of ordinary shares in issue of 1,564,702,087 shares as at 31 December 2021 (2020: 481,447,200 shares).

Registration No: 201501009903 (1135238-U)

(Incorporated in Malaysia)

INTERIM FINANCIAL REPORT FOR THE FOURTH (4th) QUARTER ENDED 31 DECEMBER 2021

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY (1)

(The figures have not been audited)

	Share Capital RM'000	Merger Reserves RM'000	Non-Distr Revaluation Reserves RM'000	ibutable Warrant Reserve RM'000	Other Reserve RM'000	Distributable Retained Earnings RM'000	Total Shareholders' Equity RM'000	Non- Controlling Interests RM'000	Total Equity RM'000
<u>Unaudited</u>									
Balance as at 1 January 2021	47,356	(16,049)	-	-	-	37,068	68,375	3,085	71,460
Issue of ordinary shares	107,199	-	-	-	-	-	107,199	-	107,199
Share issuance expenses	(985)	-	-	-	-	-	(985)	-	(985)
Comprehensive income/(loss)									
-(Loss)/Profit for the year	-	-	-	-	-	(1,176)	(1,176)	1,274	98
Other comprehensive income									
-Revaluation surplus on properties, net of tax	-	-	4,598	-	-	-	4,598	-	4,598
Total comprehensive income/(loss)	-	-	4,598	-	-	(1,176)	3,422	1,274	4,696
Issue of warrants	-	-	-	29,004	(29,004)	-	-	-	-
Acquisition of subsidiary company	-	-	-	-	-	-	-	632	632
Dividend payable to non-controlling interests		-	-	-	-	-	-	(392)	(392)
Balance as at 31 December 2021	153,570	(16,049)	4,598	29,004	(29,004)	35,892	178,011	4,599	182,610
<u>Audited</u>									
Balance as at 1 January 2020	32,120	(16,049)	-	-	-	34,831	50,902	2,623	53,525
Issue of ordinary shares	15,651	-	-	-	-	-	15,651	-	15,651
Share issuance expenses	(415)	-	-	-	-	-	(415)	-	(415)
Profit for the year									
-Total comprehensive income for the year	-	-	-	-	_	2,658	2,658	658	3,316
-Approved final dividend for the year ended 31 December 2019	-	-	-	-	-	(421)	(421)	(196)	(617)
Balance as at 31 December 2020	47,356	(16,049)	-		_	37,068	68,375	3,085	71,460

Notes:

(1) The Unaudited Condensed Consolidated Statement of Changes in Equity should be read in conjunction with the audited financial statements of the BCM Group for the FYE 31 December 2020 as well as the accompanying explanatory notes attached to this interim financial report.

Registration No: 201501009903 (1135238-U)

(Incorporated in Malaysia)

INTERIM FINANCIAL REPORT FOR THE FOURTH (4th) QUARTER ENDED 31 DECEMBER 2021

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (1)

(The figures have not been audited)

Cash Flows From Operating Activities Profit before taxation 2,256 4,613 Adjustments for: 3 1 Bad debts written off - 12 Depreciation of property, plant and equipment 1,147 1,030 Depreciation of injcht-of-use assets 1,537 1,570 Depreciation of investment properties: - - -Current 66 9 -Overstated in prior years (94) - Gain on disposal of property, plant and equipment - (7 Gain on disposal of right-of-use assets (149) (205) Income from rent concession (5 (49) Inventory written down - 20 Interest expenses 556 394 Interest expenses 556 394 Interest income (756) (320) Gain on disposal of quoted investments - realised (694) - Unrealised gain on disposal of quoted investments (81) - Impairment loss on financial instruments (31) (81)		(Unaudited) 12 months ended 31 December 2021 RM'000	(Audited) 12 months ended 31 December 2020 RM'000
Adjustments for: Bad debts written off - 12 Depreciation of property, plant and equipment 1,147 1,030 Depreciation of right-of-use assets 1,537 1,570 Depreciation of investment properties: - - -Current 66 9 -Overstated in prior years (94) - Gain on disposal of property, plant and equipment - (7) Gain on disposal of right-of-use assets (149) (2055) Income from rent concession (5) (49) Inventory written down - 20 Interest expenses 556 394 Interest income (756) (320) Gain on disposal of quoted investments - realised (694) - Unrealised gain on disposal of quoted investments (81) - Impairment loss on financial instruments (81) - Reversal of impairment loss on financial instruments (314) (10) Reversal of impairment loss on foreign exchange differences (206) 7 Operating profit before working capital changes (206) 7 Changes in working capital:<			
Bad debts written off - 12 Depreciation of property, plant and equipment 1,147 1,030 Depreciation of injent-of-use assets 1,537 1,570 Depreciation of investment properties: - - -Current 66 9 -Overstated in prior years (94) - Gain on disposal of property, plant and equipment - (7) Gain on disposal of right-of-use assets (149) (205) Income from rent concession (5) (49) Inventory written down - 20 Interest expenses 556 394 Interest income (756) (320) Gain on disposal of quoted investments - realised (694) - Unrealised gain on disposal of quoted investments (81) - Impairment loss on financial instruments (81) - Impairment loss on financial instruments (314) (10) Reversal of impairment loss on financial instruments (314) (10) Reversal of inventory written down - (4)	Profit before taxation	2,256	4,613
Depreciation of property, plant and equipment 1,147 1,030 Depreciation of right-of-use assets 1,537 1,570 Depreciation of investment properties:	Adjustments for:		
Depreciation of right-of-use assets 1,537 1,570 Depreciation of investment properties: -Current 66 9 -Overstated in prior years (94) - Gain on disposal of property, plant and equipment - (7) Gain on disposal of right-of-use assets (149) (205) Income from rent concession (5) (49) Inventory written down - 20 Interest expenses 556 394 Interest income (756) (320) Gain on disposal of quoted investments - realised (694) - Unrealised gain on disposal of quoted investments (81) - Impairment loss on financial instruments 219 183 Property, plant and equipment written off 417 68 Reversal of impairment loss on financial instruments (314) (10) Reversal of inventory written down - (4) Unrealised (gain)/loss on foreign exchange differences (206) 7 Operating profit before working capital: (11,199) 2,906 Trade receivables		-	12
Depreciation of investment properties: -Current		1,147	1,030
-Current 66 9 -Overstated in prior years (94) - Gain on disposal of property, plant and equipment - (7) Gain on disposal of right-of-use assets (149) (205) Income from rent concession (5) (49) Inventory written down - 20 Interest expenses 556 394 Interest income (756) (320) Gain on disposal of quoted investments - realised (694) - Unrealised gain on disposal of quoted investments (81) - Impairment loss on financial instruments (81) - Impairment loss on financial instruments (31) (10) Reversal of impairment loss on financial instruments (314) (10) Reversal of inventory written down - (4) Unrealised (gain)/loss on foreign exchange differences (206) 7 Operating profit before working capital changes 3,899 7,311 Changes in working capital: (11,199) 2,906 Trade receivables (2,860) 2,153	•	1,537	1,570
-Overstated in prior years (94) - Gain on disposal of property, plant and equipment - (7) Gain on disposal of right-of-use assets (149) (205) Income from rent concession (5) (49) Inventory written down - 20 Interest expenses 556 394 Interest income (756) (320) Gain on disposal of quoted investments - realised (694) - Unrealised gain on disposal of quoted investments (81) - Impairment loss on financial instruments (81) - Impairment loss on financial instruments 219 183 Property, plant and equipment written off 417 68 Reversal of impairment loss on financial instruments (314) (10) Reversal of inventory written down - (4) Unrealised (gain)/loss on foreign exchange differences (206) 7 Operating profit before working capital changes 3,899 7,311 Changes in working capital: (11,199) 2,906 Trade receivables (36,3			
Gain on disposal of property, plant and equipment - (7) Gain on disposal of right-of-use assets (149) (205) Income from rent concession (5) (49) Inventory written down - 20 Interest expenses 556 394 Interest income (756) (320) Gain on disposal of quoted investments - realised (694) - Unrealised gain on disposal of quoted investments (81) - Impairment loss on financial instruments 219 183 Property, plant and equipment written off 417 68 Reversal of impairment loss on financial instruments (314) (10) Reversal of inventory written down - (4) Unrealised (gain)/loss on foreign exchange differences (206) 7 Operating profit before working capital changes 3,899 7,311 Changes in working capital: (11,199) 2,906 Trade receivables (2,860) 2,153 Other receivables (36,361) (234) Contract liabilities (114) (21) Trade payables (1,663) (2			9
Gain on disposal of right-of-use assets (149) (205) Income from rent concession (5) (49) Inventory written down - 20 Interest expenses 556 394 Interest income (756) (320) Gain on disposal of quoted investments - realised (694) - Unrealised gain on disposal of quoted investments (81) - Impairment loss on financial instruments 219 183 Property, plant and equipment written off 417 68 Reversal of impairment loss on financial instruments (314) (10) Reversal of inventory written down - (4) Unrealised (gain)/loss on foreign exchange differences (206) 7 Operating profit before working capital changes 3,899 7,311 Changes in working capital: (11,199) 2,906 Trade receivables (2,860) 2,153 Other receivables (36,361) (234) Contract liabilities (114) (21) Trade payables (1,663) (2,484) Other payables (1,663) (2,484)	• •	(94)	-
Income from rent concession (5) (49) Inventory written down - 20 Interest expenses 556 394 Interest income (756) (320) Gain on disposal of quoted investments - realised (694) - Unrealised gain on disposal of quoted investments (81) - Impairment loss on financial instruments 219 183 Property, plant and equipment written off 417 68 Reversal of impairment loss on financial instruments (314) (10) Reversal of inventory written down - (4) Unrealised (gain)/loss on foreign exchange differences (206) 7 Operating profit before working capital changes 3,899 7,311 Changes in working capital: Inventories (11,199) 2,906 Trade receivables (2,860) 2,153 Other receivables (36,361) (234) Contract liabilities (114) (21) Trade payables (1,663) (2,484) Other payables (1,663) (2,484) Amount due to directors (40,508) (4,555) <td></td> <td>-</td> <td></td>		-	
Inventory written down - 20 Interest expenses 556 394 Interest income (756) (320) Gain on disposal of quoted investments - realised (694) - Unrealised gain on disposal of quoted investments (81) - Impairment loss on financial instruments 219 183 Property, plant and equipment written off 417 68 Reversal of impairment loss on financial instruments (314) (10) Reversal of inventory written down - (4) Unrealised (gain)/loss on foreign exchange differences (206) 7 Operating profit before working capital changes 3,899 7,311 Changes in working capital: (11,199) 2,906 Trade receivables (2,860) 2,153 Other receivables (36,361) (234) Contract liabilities (114) (21) Trade payables (1,663) (2,484) Other payables (1,663) (2,484) Amount due to directors (40,508) (4,555)			
Interest expenses 556 394 Interest income (756) (320) Gain on disposal of quoted investments - realised (694) - Unrealised gain on disposal of quoted investments (81) - Impairment loss on financial instruments 219 183 Property, plant and equipment written off 417 68 Reversal of impairment loss on financial instruments (314) (10) Reversal of inventory written down - (4) Unrealised (gain)/loss on foreign exchange differences (206) 7 Operating profit before working capital changes 3,899 7,311 Changes in working capital: (11,199) 2,906 Trade receivables (2,860) 2,153 Other receivables (36,361) (234) Contract liabilities (114) (21) Trade payables (1,663) (2,484) Other payables (1,663) (2,484) Amount due to directors (40,508) (4,555)		(5)	
Interest income (756) (320) Gain on disposal of quoted investments - realised (694) - Unrealised gain on disposal of quoted investments (81) - Impairment loss on financial instruments 219 183 Property, plant and equipment written off 417 68 Reversal of impairment loss on financial instruments (314) (10) Reversal of inventory written down - (4) Unrealised (gain)/loss on foreign exchange differences (206) 7 Operating profit before working capital changes 3,899 7,311 Changes in working capital: (11,199) 2,906 Trade receivables (2,860) 2,153 Other receivables (36,361) (234) Contract liabilities (114) (21) Trade payables (1,443) (6,875) Other payables (1,663) (2,484) Amount due to directors 246 - (40,508) (4,555)	•	-	
Gain on disposal of quoted investments - realised (694) - Unrealised gain on disposal of quoted investments (81) - Impairment loss on financial instruments 219 183 Property, plant and equipment written off 417 68 Reversal of impairment loss on financial instruments (314) (10) Reversal of inventory written down - (4) Unrealised (gain)/loss on foreign exchange differences (206) 7 Operating profit before working capital changes 3,899 7,311 Changes in working capital: (11,199) 2,906 Trade receivables (2,860) 2,153 Other receivables (36,361) (234) Contract liabilities (114) (21) Trade payables 11,443 (6,875) Other payables (1,663) (2,484) Amount due to directors 246 - (40,508) (4,555)	·		
Unrealised gain on disposal of quoted investments Impairment loss on financial instruments Property, plant and equipment written off Reversal of impairment loss on financial instruments Reversal of inventory written down Qurrealised (gain)/loss on foreign exchange differences Operating profit before working capital changes Changes in working capital: Inventories Inventories Trade receivables Other receivables Contract liabilities Other payables Other payables Amount due to directors (81) - (10) 8417 68 (314) (10) (20) 7 (206) 7 (206) 7 (211,199) 2,906 (2,860) 2,153 (2,860) 2,153 (36,361) (234) (234) (5,875) (40,508) (4,555)			(320)
Impairment loss on financial instruments 219 183 Property, plant and equipment written off 417 68 Reversal of impairment loss on financial instruments (314) (10) Reversal of inventory written down - (4) Unrealised (gain)/loss on foreign exchange differences (206) 7 Operating profit before working capital changes 3,899 7,311 Changes in working capital: (11,199) 2,906 Trade receivables (2,860) 2,153 Other receivables (36,361) (234) Contract liabilities (114) (21) Trade payables (1,663) (2,484) Other payables (1,663) (2,484) Amount due to directors 246 - (40,508) (4,555)			_
Property, plant and equipment written off 417 68 Reversal of impairment loss on financial instruments (314) (10) Reversal of inventory written down - (4) Unrealised (gain)/loss on foreign exchange differences (206) 7 Operating profit before working capital changes 3,899 7,311 Changes in working capital: (11,199) 2,906 Trade receivables (2,860) 2,153 Other receivables (36,361) (234) Contract liabilities (114) (21) Trade payables 11,443 (6,875) Other payables (1,663) (2,484) Amount due to directors 246 - (40,508) (4,555)			183
Reversal of impairment loss on financial instruments (314) (10) Reversal of inventory written down - (4) Unrealised (gain)/loss on foreign exchange differences (206) 7 Operating profit before working capital changes 3,899 7,311 Changes in working capital: (11,199) 2,906 Trade receivables (2,860) 2,153 Other receivables (36,361) (234) Contract liabilities (114) (21) Trade payables 11,443 (6,875) Other payables (1,663) (2,484) Amount due to directors 246 - (40,508) (4,555)	•		
Reversal of inventory written down - (4) Unrealised (gain)/loss on foreign exchange differences (206) 7 Operating profit before working capital changes 3,899 7,311 Changes in working capital: Inventories (11,199) 2,906 Trade receivables (2,860) 2,153 Other receivables (36,361) (234) Contract liabilities (114) (21) Trade payables 11,443 (6,875) Other payables (1,663) (2,484) Amount due to directors 246 - (40,508) (4,555)			
Unrealised (gain)/loss on foreign exchange differences (206) 7 Operating profit before working capital changes 3,899 7,311 Changes in working capital: Inventories (11,199) 2,906 Trade receivables (2,860) 2,153 Other receivables (36,361) (234) Contract liabilities (114) (21) Trade payables 11,443 (6,875) Other payables (1,663) (2,484) Amount due to directors 246 - (40,508) (4,555)	·	(311)	
Operating profit before working capital changes 3,899 7,311 Changes in working capital:	·	(206)	
Changes in working capital: (11,199) 2,906 Trade receivables (2,860) 2,153 Other receivables (36,361) (234) Contract liabilities (114) (21) Trade payables 11,443 (6,875) Other payables (1,663) (2,484) Amount due to directors 246 - (40,508) (4,555)			
Inventories (11,199) 2,906 Trade receivables (2,860) 2,153 Other receivables (36,361) (234) Contract liabilities (114) (21) Trade payables 11,443 (6,875) Other payables (1,663) (2,484) Amount due to directors 246 - (40,508) (4,555)		2,222	.,
Trade receivables (2,860) 2,153 Other receivables (36,361) (234) Contract liabilities (114) (21) Trade payables 11,443 (6,875) Other payables (1,663) (2,484) Amount due to directors 246 - (40,508) (4,555)		(11 100)	2 006
Other receivables (36,361) (234) Contract liabilities (114) (21) Trade payables 11,443 (6,875) Other payables (1,663) (2,484) Amount due to directors 246 - (40,508) (4,555)			
Contract liabilities (114) (21) Trade payables 11,443 (6,875) Other payables (1,663) (2,484) Amount due to directors 246 - (40,508) (4,555)			
Trade payables 11,443 (6,875) Other payables (1,663) (2,484) Amount due to directors 246 - (40,508) (4,555)			
Other payables (1,663) (2,484) Amount due to directors 246 - (40,508) (4,555)			
Amount due to directors 246 - (40,508) (4,555)		-	
(40,508) (4,555)			(2, 101)
	, 220 CC 411 CCC10		(4,555)
	Cash (used in)/generated from operations carried forward		

Registration No: 201501009903 (1135238-U)

(Incorporated in Malaysia)

INTERIM FINANCIAL REPORT FOR THE FOURTH (4th) QUARTER ENDED 31 DECEMBER 2021

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (Continued) (1) (The figures have not been audited)

Increase in fixed deposit pledged with licensed banks Repayment of bank borrowings Repayment of lease liabilities (1,925) (48) (249) (1,630)		(Unaudited) 12 months ended 31 December 2021 RM'000	(Audited) 12 months ended 31 December 2020 RM'000
Interest paid (556) 320 Tax paid (2,158) (1,976) Tax refund 39 484 (1,919) (1,566) Net cash (used in)/generated from operating activities (38,528) 1,190 Cash Flows From Investing Activities Purchase of property, plant and equipment (2,477) (1,195) Purchase of iright-of-use assets (118) (55) Purchase of intangible assets (19,024) - Proceeds from disposal of property, plant and equipment - 483 Proceeds from disposal of right-of-use assets 500 16 Proceeds from disposal of quoted investments 18,988 - Purchase of investment in quoted shares (44,549) - Acquisition of subsidiary companies, net of cash (366) - Net cash used in investing activities (47,046) (751) Cash Flows From Financing Activities - 1,964 Proceeds from bank borrowings - 1,964 Proceeds from bank borrowings - 1,964 Proceeds from bank	Cash (used in)/generated from operations brought forward	(36,609)	2,756
Interest paid (556) 320 Tax paid (2,158) (1,976) Tax refund 39 484 (1,919) (1,566) Net cash (used in)/generated from operating activities (38,528) 1,190 Cash Flows From Investing Activities Purchase of property, plant and equipment (2,477) (1,195) Purchase of iright-of-use assets (118) (55) Purchase of intangible assets (19,024) - Proceeds from disposal of property, plant and equipment - 483 Proceeds from disposal of right-of-use assets 500 16 Proceeds from disposal of quoted investments 18,988 - Purchase of investment in quoted shares (44,549) - Acquisition of subsidiary companies, net of cash (366) - Net cash used in investing activities (47,046) (751) Cash Flows From Financing Activities - 1,964 Proceeds from bank borrowings - 1,964 Proceeds from bank borrowings - 1,964 Proceeds from bank	Interest received	756	(394)
Tax paid (2,158) (1,976) Tax refund 39 484 (1,919) (1,566) Net cash (used in)/generated from operating activities (38,528) 1,190 Cash Flows From Investing Activities Purchase of property, plant and equipment (2,477) (1,195) Purchase of right-of-use assets (118) (55) Purchase of intangible assets (19,024) - Proceeds from disposal of property, plant and equipment - 483 Proceeds from disposal of right-of-use assets 500 16 Proceeds from disposal of quoted investments 18,988 - Purchase of investment in quoted shares (44,549) - Acquisition of subsidiary companies, net of cash (366) - Net cash used in investing activities (47,046) (751) Cash Flows From Financing Activities Proceeds from bank borrowings - 1,964 Proceeds from issue of ordinary shares 107,200 15,651 Share issuance expenses (986) (415) Dividend paid			
Tax refund 39 484 (1,919) (1,566) Net cash (used in)/generated from operating activities (38,528) 1,190 Cash Flows From Investing Activities Purchase of property, plant and equipment (2,477) (1,195) Purchase of right-of-use assets (118) (55) Purchase of intangible assets (19,024) - Proceeds from disposal of property, plant and equipment - 483 Proceeds from disposal of right-of-use assets 500 16 Proceeds from disposal of quoted investments 18,988 - Purchase of investment in quoted shares (44,549) - Acquisition of subsidiary companies, net of cash (366) - Net cash used in investing activities (47,046) (751) Cash Flows From Financing Activities Proceeds from bank borrowings - 1,964 Proceeds from issue of ordinary shares 107,200 15,651 Share issuance expenses (986) (415) Dividend paid - (421) Dividend paid to non-con	•		
Net cash (used in)/generated from operating activities (38,528) 1,190 Cash Flows From Investing Activities Purchase of property, plant and equipment (2,477) (1,195) Purchase of right-of-use assets (118) (55) Purchase of intangible assets (19,024) - Proceeds from disposal of property, plant and equipment - 483 Proceeds from disposal of right-of-use assets 500 16 Proceeds from disposal of quoted investments 18,988 - Purchase of investment in quoted shares (44,549) - Acquisition of subsidiary companies, net of cash (366) - Net cash used in investing activities (47,046) (751) Cash Flows From Financing Activities Proceeds from issue of ordinary shares 107,200 15,651 Share issuance expenses (986) (415) Dividend paid to non-controlling interest - (88) Increase in fixed deposit pledged with licensed banks (31) (48) Repayment of bank borrowings (921) (249) Repayment of lease liabilities (1,925) (1,630)	•		
Net cash (used in)/generated from operating activities Cash Flows From Investing Activities Purchase of property, plant and equipment Purchase of right-of-use assets (118) Purchase of intangible assets (19,024) Proceeds from disposal of property, plant and equipment Proceeds from disposal of right-of-use assets Purchase of investment in quoted investments Purchase of investment in quoted shares Purchase of investment in quoted shares Purchase of investment in quoted shares Acquisition of subsidiary companies, net of cash Net cash used in investing activities Cash Flows From Financing Activities Proceeds from issue of ordinary shares Proceeds from issue of ordinary shares Share issuance expenses (986) Dividend paid Proceeds from inconduction interest Dividend paid to non-controlling interest Procease in fixed deposit pledged with licensed banks Repayment of bank borrowings (921) Repayment of lease liabilities (1,925) (1,630)		(1,919)	(1,566)
Purchase of property, plant and equipment (2,477) (1,195) Purchase of right-of-use assets (118) (55) Purchase of intangible assets (19,024) - Proceeds from disposal of property, plant and equipment - 483 Proceeds from disposal of right-of-use assets 500 16 Proceeds from disposal of quoted investments 18,988 - Purchase of investment in quoted shares (44,549) - Acquisition of subsidiary companies, net of cash (366) - Net cash used in investing activities (47,046) (751) Cash Flows From Financing Activities Proceeds from bank borrowings - 1,964 Proceeds from issue of ordinary shares 107,200 15,651 Share issuance expenses (986) (415) Dividend paid - (421) Dividend paid to non-controlling interest - (88) Increase in fixed deposit pledged with licensed banks Repayment of bank borrowings (921) (249) Repayment of lease liabilities (1,925) (1,630)	Net cash (used in)/generated from operating activities	(38,528)	
Purchase of property, plant and equipment (2,477) (1,195) Purchase of right-of-use assets (118) (55) Purchase of intangible assets (19,024) - Proceeds from disposal of property, plant and equipment - 483 Proceeds from disposal of right-of-use assets 500 16 Proceeds from disposal of quoted investments 18,988 - Purchase of investment in quoted shares (44,549) - Acquisition of subsidiary companies, net of cash (366) - Net cash used in investing activities (47,046) (751) Cash Flows From Financing Activities Proceeds from bank borrowings - 1,964 Proceeds from issue of ordinary shares 107,200 15,651 Share issuance expenses (986) (415) Dividend paid - (421) Dividend paid to non-controlling interest - (88) Increase in fixed deposit pledged with licensed banks Repayment of bank borrowings (921) (249) Repayment of lease liabilities (1,925) (1,630)	Cash Flows From Investing Activities		
Purchase of right-of-use assets (118) (55) Purchase of intangible assets (19,024) - Proceeds from disposal of property, plant and equipment - 483 Proceeds from disposal of right-of-use assets 500 16 Proceeds from disposal of quoted investments 18,988 - Purchase of investment in quoted shares (44,549) - Acquisition of subsidiary companies, net of cash (366) - Net cash used in investing activities (47,046) (751) Cash Flows From Financing Activities Proceeds from bank borrowings - 1,964 Proceeds from issue of ordinary shares 107,200 15,651 Share issuance expenses (986) (415) Dividend paid - (421) Dividend paid to non-controlling interest - (88) Increase in fixed deposit pledged with licensed banks Repayment of bank borrowings (921) (249) Repayment of lease liabilities (1,925) (1,630)		(2,477)	(1,195)
Purchase of intangible assets Proceeds from disposal of property, plant and equipment Proceeds from disposal of right-of-use assets Proceeds from disposal of quoted investments Proceeds from disposal of quoted investments Purchase of investment in quoted shares Acquisition of subsidiary companies, net of cash Net cash used in investing activities Proceeds from bank borrowings Proceeds from bank borrowings Proceeds from issue of ordinary shares Proceeds from issue of ordinary shares Prividend paid Proceeds from bank borrowings Proceeds from issue of ordinary shares Proceeds from bank borrowings Proceeds from issue of ordinary shares Proceeds from issue of ordinary shares Proceeds from issue of ordinary shares Proceeds from bank borrowings Proceeds from issue of ordinary shares Proceeds from issue of ordinary shares Proceeds from bank borrowings Proceeds from issue of ordinary shares Proceeds from issue			
Proceeds from disposal of property, plant and equipment Proceeds from disposal of right-of-use assets Proceeds from disposal of quoted investments Purchase of investment in quoted shares Acquisition of subsidiary companies, net of cash Net cash used in investing activities Cash Flows From Financing Activities Proceeds from bank borrowings Proceeds from issue of ordinary shares Proceeds from issue of ordinary shares Proceeds from issue of ordinary shares Proceeds issuance expenses (986) Dividend paid Dividend paid to non-controlling interest Increase in fixed deposit pledged with licensed banks Repayment of bank borrowings (921) Repayment of lease liabilities (1,925) (1,630)			-
Proceeds from disposal of right-of-use assets Proceeds from disposal of quoted investments 18,988 - Purchase of investment in quoted shares Acquisition of subsidiary companies, net of cash Net cash used in investing activities Cash Flows From Financing Activities Proceeds from bank borrowings Proceeds from issue of ordinary shares Share issuance expenses Dividend paid Dividend paid to non-controlling interest Increase in fixed deposit pledged with licensed banks Repayment of bank borrowings Repayment of lease liabilities 1644,549) - (447,046) - (47,046) - (47,046) - (47,046) - (751) 1964 - 1,964 - (986) - (415) - (421)		-	483
Proceeds from disposal of quoted investments Purchase of investment in quoted shares Acquisition of subsidiary companies, net of cash Net cash used in investing activities Cash Flows From Financing Activities Proceeds from bank borrowings Proceeds from issue of ordinary shares Share issuance expenses Dividend paid Dividend paid to non-controlling interest Increase in fixed deposit pledged with licensed banks Repayment of bank borrowings Repayment of lease liabilities 18,988 - (44,549) - (47,046) - (47,046) - (751) 1,964 - (751) - (1,964) - (1,965) - (1,965) - (1,965) - (1,965) - (1,966) - (1,925) - (1,630)		500	16
Purchase of investment in quoted shares Acquisition of subsidiary companies, net of cash Net cash used in investing activities Cash Flows From Financing Activities Proceeds from bank borrowings Proceeds from issue of ordinary shares Share issuance expenses Dividend paid Dividend paid to non-controlling interest Increase in fixed deposit pledged with licensed banks Repayment of lease liabilities (44,549) - (47,046) (751) 1,964 Proceeds from issue of ordinary shares 107,200 15,651 Share issuance expenses (986) (415) Dividend paid - (421) Dividend paid - (88) Increase in fixed deposit pledged with licensed banks (31) (48) Repayment of lease liabilities (1,925) (1,630)	·	18,988	-
Acquisition of subsidiary companies, net of cash Net cash used in investing activities Cash Flows From Financing Activities Proceeds from bank borrowings Proceeds from issue of ordinary shares Share issuance expenses Dividend paid Dividend paid Dividend paid to non-controlling interest Increase in fixed deposit pledged with licensed banks Repayment of bank borrowings Repayment of lease liabilities (366) (47,046) (751) 1,964 Proceeds from bank borrowings (986) (415) (421) (-
Net cash used in investing activities (47,046) (751) Cash Flows From Financing Activities Proceeds from bank borrowings - 1,964 Proceeds from issue of ordinary shares 107,200 15,651 Share issuance expenses (986) (415) Dividend paid - (421) Dividend paid to non-controlling interest - (88) Increase in fixed deposit pledged with licensed banks (31) (48) Repayment of bank borrowings (921) (249) Repayment of lease liabilities (1,925) (1,630)	·	(366)	-
Proceeds from bank borrowings - 1,964 Proceeds from issue of ordinary shares 107,200 15,651 Share issuance expenses (986) (415) Dividend paid - (421) Dividend paid to non-controlling interest - (88) Increase in fixed deposit pledged with licensed banks Repayment of bank borrowings (921) (249) Repayment of lease liabilities (1,925) (1,630)	Net cash used in investing activities		(751)
Proceeds from issue of ordinary shares 107,200 15,651 Share issuance expenses (986) (415) Dividend paid - (421) Dividend paid to non-controlling interest - (88) Increase in fixed deposit pledged with licensed banks Repayment of bank borrowings (921) (249) Repayment of lease liabilities (1,925) (1,630)	Cash Flows From Financing Activities		
Share issuance expenses (986) (415) Dividend paid - (421) Dividend paid to non-controlling interest - (88) Increase in fixed deposit pledged with licensed banks Repayment of bank borrowings (921) (249) Repayment of lease liabilities (1,925) (1,630)	Proceeds from bank borrowings	-	1,964
Dividend paid - (421) Dividend paid to non-controlling interest - (88) Increase in fixed deposit pledged with licensed banks Repayment of bank borrowings (921) (249) Repayment of lease liabilities (1,925) (1,630)	Proceeds from issue of ordinary shares	107,200	15,651
Dividend paid to non-controlling interest - (88) Increase in fixed deposit pledged with licensed banks Repayment of bank borrowings (921) (249) Repayment of lease liabilities (1,925) (1,630)	Share issuance expenses	(986)	(415)
Increase in fixed deposit pledged with licensed banks Repayment of bank borrowings Repayment of lease liabilities (31) (48) (249) (1,925) (1,630)	Dividend paid	-	(421)
Repayment of bank borrowings (921) (249) Repayment of lease liabilities (1,925) (1,630)	Dividend paid to non-controlling interest	-	(88)
Repayment of lease liabilities (1,925) (1,630)	Increase in fixed deposit pledged with licensed banks	(31)	(48)
	Repayment of bank borrowings	(921)	(249)
Net cash generated from financing activities 103,337 14,764	Repayment of lease liabilities	(1,925)	(1,630)
	Net cash generated from financing activities	103,337	14,764

Registration No: 201501009903 (1135238-U)

(Incorporated in Malaysia)

INTERIM FINANCIAL REPORT FOR THE FOURTH (4th) QUARTER ENDED 31 DECEMBER 2021

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (Continued) (1) (The figures have not been audited)

	(Unaudited) 12 months ended 31 December 2021 RM'000	(Audited) 12 months ended 31 December 2020 RM'000
Net increase in cash and cash equivalents	17,763	15,203
Effects of exchange differences on cash and cash equivalents	-	(2)
Cash and cash equivalents at the beginning of the year	45,756	30,555
Cash and cash equivalents at the end of the year	63,519	45,756
Cash and cash equivalents at the end of the year comprises:		
- Fixed deposits with licensed banks	39,686	1,815
- Cash and bank balances	25,935	45,756
- Bank overdraft	(256)	
	65,365	47,571
Less: Fixed deposits pledged with licensed banks	(1,846)	(1,815)
Net cash and cash equivalent at the end of the year	63,519	45,756

Note:

(1) The Unaudited Condensed Consolidated Statement of Cash Flows should be read in conjunction with the audited financial statements of the Group for the FYE 31 December 2020 as well as the accompanying explanatory notes attached to this interim financial report.

Registration No: 201501009903 (1135238-U)

(Incorporated in Malaysia)

INTERIM FINANCIAL REPORT FOR THE FOURTH (4th) QUARTER ENDED 31 DECEMBER 2021

NOTES TO THE INTERIM FINANCIAL REPORT

A. EXPLANATORY NOTES TO THE UNAUDITED INTERIM FINANCIAL REPORT

A1. Basis of preparation

The interim financial statements are unaudited and have been prepared in accordance with the requirements of Malaysian Financial Reporting Standards ("MFRS") No. 134: Interim Financial Reporting and Rules 9.22 and Appendix 9B of the ACE Market Listing Requirements of Bursa Malaysia Securities Berhad ("Listing Requirement").

The interim financial statements should be read in conjunction with the audited financial statements for the FYE 31 December 2020 and the accompanying explanatory notes attached to this interim financial report.

The accounting policies adopted in the interim financial statements are consistent with those adopted in the audited financial statements for the FYE 31 December 2020. The Group has adopted those standards, amendments and interpretations that have become effective and such adoptions do not have material impact on the financial position and performance of the Group.

Adoption of new and amended standard

During the financial year, the Group has adopted the following amendments for MFRSs issued by the Malaysian Accounting Standards Board ("MASB") that are mandatory for current financial year.

Amendments to MFRS 9, MFRS 139, MFRS 7, MFRS 4 and MFRS 16 Interest Rate Benchmark Reform - Phase 2

Amendments to MFRS 16

Covid-19 - Related Rent Concessions Beyond 30 June 2021

Adoption of the above amendments to MFRSs did not have any significant impact on the financial statements of the Group.

Registration No: 201501009903 (1135238-U)

(Incorporated in Malaysia)

INTERIM FINANCIAL REPORT FOR THE FOURTH (4th) QUARTER ENDED 31 DECEMBER 2021

A1. Basis of preparation (continued)

Standards issued but not yet effective

The Group has not applied the following standards, amendments and interpretations under MFRS framework that have been issued by the MASB as they have yet to be effective for the Group.

Group.		Effective dates for financial year
MFRSs and IC Interpreta Amendments)	tions (Including The Consequential	beginning on and after
Amendments to MFRS 3	Reference to the Conceptual Framework	1 January 2022
Amendments to MFRS 116	Property, Plant and Equipment-Proceeds before Intended Use	1 January 2022
Amendments to MFRS 137	Onerous Contracts-Cost of Fulfilling a Contract	1 January 2022
Annual improvements to MFRS Standards 2018- 2020:- -Amendments to MFRS 1 -Amendments to MFRS 9 -Amendments to MFRS 16 -Amendments to MFRS 141		1 January 2022
MFRS 17	Insurance Contracts	1 January 2023
Amendments to MFRS 17	Insurance Contracts	1 January 2023
Amendments to MFRS 101	Classification of Liabilities as Current or Non-current	1 January 2023
Amendments to MFRS 101	Disclosure of Accounting Policies	1 January 2023
Amendments to MFRS 108	Definition of Accounting Estimates	1 January 2023
Amendments to MFRS 112	Deferred Tax related to Assets and Liabilities arising from a Single Transaction	1 January 2023
Amendments to MFRS 10 and MFRS 128	Sales or Contribution of Assets between an Investor and its Associate or Joint Venture	Deferred until further notice

A2. Auditors' report of preceding annual audited financial statements

The audited financial statements of the Group for the FYE 31 December 2020 were not subject to any qualification.

Registration No: 201501009903 (1135238-U)

(Incorporated in Malaysia)

INTERIM FINANCIAL REPORT FOR THE FOURTH (4th) QUARTER ENDED 31 DECEMBER 2021

A3. Seasonal or cyclical factors

The financial performance of the Group was not affected by seasonal or cyclical factors during the current financial quarter and financial period-to-date.

A4. Unusual items

There were no unusual items affecting assets, liabilities, equity, net income or cash flows of the Group during the current financial guarter and financial period-to-date.

A5. Material changes in estimates

There were no changes in the estimates of amounts reported in prior financial years that had a material effect on the current financial quarter and financial period-to-date.

A6. Debt and equity securities

There were no issuance, cancellation, repurchase, resale and repayment of debt and equity securities for the current financial guarter and financial period to-date.

A7. Segmental information

The Group's reportable segments comprise of commercial laundry equipment, medical devices, healthcare products, investment holding, laundry services, health food and beverage ("Health F&B") and other (represented an entity which yet to commence operation).

For each reportable segment, the Group's chief operating decision makers which is the Board of Directors of the Company, reviews internal management reports on quarterly basis.

Registration No: 201501009903 (1135238-U)

(Incorporated in Malaysia)

INTERIM FINANCIAL REPORT FOR THE FOURTH (4th) QUARTER ENDED 31 DECEMBER 2021

A7. Segmental information (continued)

Results for the 3 months ended 31 December

In RM'000																		
	Q4 2021 (Una	udited)								Q4 2020 (Unau	idited)							
Business Segments	Commercial	Medical	Healthcare	Investment	Laundry	Health	Other	Adjustment	Total	Commercial	Medical	Healthcare	Investment	Laundry	Health	Others	Adjustment	Total
	Laundry	Devices	Products	Holding	Services	F&B		&	Group	Laundry	Devices	Products	Holding	Services	F&B		&	Group
	Equipment							Elimination		Equipment							Elimination	
Revenue (i) external customers	4,694	7,926	11,143	-	261	1,529	-	-	25,553	7,029	5,722	2,741	-	210	-	-	-	15,702
(ii) inter-segment	378	40	-	1,245		-		(1,663)	-	18	39	-	981	-	-	-	(1,038)	
Total Revenue	5,072	7,966	11,143	1,245	261	1,529	-	(1,663)	25,553	7,047	5,761	2,741	981	210	-	-	(1,038)	15,702
Results-Segment results	724	1,100	2,827	2,733	(3,396)	(440)	(5)	(485)	3,058	(144)	635	36	220	(6)	-	(2)	(169)	570
Interest income	15	10	24	152	63	٨	-	-	264	39	11	7	24	-	-	-	-	81
Finance costs	(12)	(38)	(34)	(10)	(4)	(40)	-	-	(138)	(55)	(108)	(25)	(10)	(14)	-	-	-	(212)
Profit/(Loss) before taxation	727	1,072	2,817	2,875	(3,337)	(480)	(5)	(485)	3,184	(160)	538	18	234	(20)	-	(2)	(169)	439
Taxation	(258)	(227)	(137)	(65)	(15)	-	-	-	(702)	34	(184)	6	-	2	-	-	-	(142)
Profit/(Loss) after taxation	469	845	2,680	2,810	(3,352)	(480)	(5)	(485)	2,482	(126)	354	24	234	(18)	-	(2)	(169)	297
Other non cash items:																		
-Depreciation of property, plant and equipment	(66)		(65)	(21)	(98)	5	-	15	(314)	(72)	(90)	(25)	(13)		-	-	36	(250)
-Depreciation of right-of-use assets	(61)	(104)	(46)	(80)	(60)	(6)	-	-	(357)	(124)	(86)	(48)	(57)	(64)	-	-	-	(379)
-Depreciation of investment properties:																		
-current	-	(1)	-	-	-	(37)	-	-	(38)	-	-	-	-	-	-	-	-	-
-overstated in prior years	-	-	-	-	-	17	-	-	17	-	-	-	-	-	-	-	-	-
-Gain on disposal of property, plant and equipment	-	-	-	-	-	-	-	-	-	-	-	1	-	-	-	-	-	1
-Gain on disposal of right-of-use assets	17	129	-	-	-	-	-	-	146	-	-	-	-	-		-	-	-
-Gain on disposal of quoted investments-realised	-	-	-	6,594	-	-	-	-	6,594	-	-	-	-	-	-	-	-	-
-Unrealised loss on disposal of quoted investments	-	-	-	(4,172)	-	-	-	-	(4,172)	-	-	-	-	-	-	-	-	-
-Unrealised gain/(loss) on foreign exchange differences	135	111	10	-	-	-	-	-	256	(108)	(4)	10	-	-		-	-	(102)
-Property, plant and equipment written off	-	-	-	-	-	(95)	-	-	(95)	-	-	(1)	-	(21)	-	-	-	(22)
-Impairment loss on financial instruments	-	-	(129)	-	-	(90)	-	-	(219)	(108)	(82)	(30)	-	-	-	-	-	(220)
-Reversal of impairment loss on financial instruments	103	140	39	-	-	32	-	-	314	-	-	-	-	-	-	-	-	-
-Reversal of inventories written down	-	-	-	-	-	-	-	-	-	-	5	-	-	-	-	-	-	5
-Reversal of fair value gain on investment property	-	(103)	-	-	-	-	-	-	(103)	-	-	-	-	-	-	-	-	-

12

[^] Represent less than RM1,000

Registration No: 201501009903 (1135238-U)

(Incorporated in Malaysia)

INTERIM FINANCIAL REPORT FOR THE FOURTH (4th) QUARTER ENDED 31 DECEMBER 2021

A7. Segmental information (continued)

33.753

36.636

(11,246) (15,479)

36.241

(29,064)

155.664

50.584

(971) (54,534)

8.125

(7,046)

4

(16)

(97.710)

77,669

223.297

(40,687)

29.437

(9,612)

34.655

(17,961)

10.775

(4,475)

49.037

(1,048)

3.524

(3,917)

(32.696)

13,744

9

(12)

94.741

(23,281)

Results for the cumulative 12 months ended 31 December

In RM'000 Q4 2021 (Unaudited) Q4 2020 (Audited) **Business Segments** Commercial Medical Healthcare Investment Laundry Health Other Adjustment Commercial Medical Healthcare Laundry Health Other Adjustment Total Devices Products Holding Services Group Laundry Products Services F&B Group Elimination Equipment Equipment Elimination 30.376 12.232 Revenue (i) external customers 18.603 25.773 26.874 744 3.265 75.259 24.809 710 68.127 (ii) inter-segment 390 74 3.168 (3.632)445 82 2.511 (3.041)18,993 25,847 26,874 3,168 744 3,265 (3,632) 75,259 25,254 30,458 12,235 2,511 710 (3,041) 68,127 **Total Revenue** 48 (3,699) (199) (6) 4,687 **Results-Segment results** 1,312 2,413 2,763 (344)(8) (429)2,056 1,533 2,180 1,782 (423)(180)Interest income 39 39 57 553 68 756 148 72 30 70 320 Finance costs (65) (162)(117)(45) (10) (157)(556)(81) (218)(55) (22) (18)(394)Profit/(Loss) before taxation 1,286 2,290 2,703 556 (3,641)(501)(8) (429)2,256 1,600 2,034 1,757 (375)(217) (6) (180)4,613 (1,046)(2,158)(393)(491) (1,297)Taxation (395)(635)(65) (17)(413)Profit/(Loss) after taxation 891 1,655 1,657 491 (3,658) (501) (8) (429) 98 1,207 1,543 1,344 (375) (217) (6) (180) 3,316 Other non cash items: -Bad debt written off (12)(12)-Depreciation of property, plant and equipment (266)(313)(169)(89) (356)(5) 51 (1,147)(282)(361)(89) (24)(320)(1,030)-Depreciation of right-of-use assets (329)(448)(186)(321)(238)(15) (1,537)(503)(471)(180)(170) (246)(1,570)-Depreciation of investment properties: (6) (60)(66)(9) (9) -overstated in prior years 94 7 (1) 7 -Gain/(loss) on disposal of property, plant and equipment -Gain on disposal of right-of-use assets 17 132 149 205 205 -Gain on disposal of quoted investments-realised 694 694 -Unrealised gain on disposal of quoted investments 81 81 95 108 (3) (3) (1) (7) -Unrealised gain/(loss) on foreign exchange differences 3 206 -Income from rent concession 5 5 18 5 8 16 49 -Inventories written down (20)(20)(3) -Property, plant and equipment written off (319)(95) (417)(68)(68)-Impairment loss on financial instruments (129)(90) (219)(70) (83) (30)(183)-Reversal of impairment loss on financial instruments 103 140 39 32 314 10 10

Segment assets

Segment liabilities

-Reversal of inventories written down

[^] Represent less than RM1,000

Registration No: 201501009903 (1135238-U)

(Incorporated in Malaysia)

INTERIM FINANCIAL REPORT FOR THE FOURTH (4th) QUARTER ENDED 31 DECEMBER 2021

A8. Dividends paid

No dividends were paid during the current guarter under review.

A9. Valuation of property, plant and equipment

The Group has not carried out any valuation on its property, plant and equipment in the current financial quarter.

A10. Capital commitments

There were no capital commitments of the Group as at 31 December 2021.

A11. Changes in the composition of the Group

There were no changes to the composition of the Group during the current financial quarter under review.

A12. Contingent liabilities and contingent assets

Since the last annual balance sheet date, there were no contingent liabilities and contingent assets as at the date of this interim financial report that are expected to have an operational or financial impact on the current financial period-to-date.

A13. Material events subsequent to the end of the quarter

Save as disclosed below, there were no other material events subsequent to the end of the current quarter and financial period-to-date that have not been reflected in the interim financial report.

Offer and grant of options under Employees' Share Option Scheme ("ESOS")

On 12 January 2022, ESOS had been granted to the eligible employees of the Company, the details as follows:

1.	Date of Offer of the Options	:	12 January 2022
2.	Exercise Price of Options offered	:	RM0.0291
3.	Number of Options offered	:	469,410,000
4.	Closing Market Price of the Company's Shares on the Date of Offer	:	RM0.035
5.	Number of Options offered to the Directors of the Company	:	Nil
6.	Vesting Period of the Options offered	:	Not applicable

On 19 January 2022, 469,410,000 new ordinary shares at RM0.26 per share on the ACE Market of Bursa Malaysia Securities Berhad. After this, number of shares and paid up share capital of the Company increased to 2,034,112,087 units and RM 167,230,259 respectively.

Registration No: 201501009903 (1135238-U)

(Incorporated in Malaysia)

INTERIM FINANCIAL REPORT FOR THE FOURTH (4th) QUARTER ENDED 31 DECEMBER 2021

A14. Related party transactions

The Group's significant related party transactions in the current period and financial period-todate under review are as follows:

(Unaudited)	(Unaudited)
Current	Cumulative
quarter ended	quarter ended
31 December	31 December
2021	2021
RM'000	RM'000

Transactions with a company in which certain directors of the Company have substantial financial interest: Lease payment on premises.

50 200

Registration No: 201501009903 (1135238-U)

(Incorporated in Malaysia)

INTERIM FINANCIAL REPORT FOR THE FOURTH (4th) QUARTER ENDED 31 DECEMBER 2021

B. ADDITIONAL INFORMATION REQUIRED BY THE LISTING REQUIREMENTS

B1. Review of performance

	Individua			
	(Unaudited)	(Unaudited)		
	31 December	31 December		
	2021	2020	Cha	inges
	RM'000	RM'000	RM'000	Percentage
Revenue	25,553	15,702	9,851	62.74%
Operating profit	130	355	(225)	(63.38%)
Profit before interest and tax	3,322	651	2,671	410.29%
Profit before tax	3,184	439	2,745	625.28%
Profit after tax	2,482	297	2,185	735.69%
Profit attributable to owners	2,611	285	2,326	816.14%
of the Company				

Current quarter (3 months)

For the current quarter ended 31 December 2021, the Group recorded revenue of RM25.55 million as compared to RM15.70 million in the corresponding quarter ended 31 December 2020, an increase of RM9.85 million or 62.74%. The higher revenue was mainly due to the increase in revenue contribution from healthcare products business segment, medical devices business segment, health food and beverage business segment and laundry services business segment.

The revenue contribution from the healthcare products business segment rose by 306.53% or RM8.40 million, from RM2.74 million in the corresponding quarter ended 31 December 2020 compared to RM11.14 million in the current quarter ended 31 December 2021. The increase in revenue was mainly due to new sales generated from virus attenuation devices and higher demand for other healthcare products as consumers became more health-conscious under the COVID-19 climate.

For the current quarter, our medical devices business segment recorded an increase in revenue by RM2.20 million or 38.52% to RM7.93 million as compared to RM5.72 million in the corresponding quarter ended 31 December 2020. The higher revenue was was mainly attributable to more orders secured from its customers for medical imaging equipment in current quarter.

The Group's new health food and beverage business segment also contributed RM1.53 million revenue in the current quarter, indicates good demand from customers for consumption of our products.

The Group's laundry services business segment increased in revenue by RM0.05 million or 24.29%. It contributed RM0.26 million revenue in the current quarter compared to RM0.21 million in the corresponding quarter ended 31 December 2020. The improvement was mainly due to good demand from customers for use of our services.

The revenue contribution from commercial laundry equipment business segment was decreased by RM2.34 million or 33.22% from RM7.03 million in the corresponding quarter ended 31 December 2020 compared to RM4.69 million in current quarter. The lower revenue was mainly due to conservative approach adopted by potential customers (more caution in their investment direction) during current economic challenging time which resulted in lower sales in current quarter.

Registration No: 201501009903 (1135238-U)

(Incorporated in Malaysia)

INTERIM FINANCIAL REPORT FOR THE FOURTH (4th) QUARTER ENDED 31 DECEMBER 2021

B1. Review of performance (continued)

Current quarter (3 months) (continued)

The Group recorded profit before tax of RM3.18 million in current quarter as compared to profit before tax of RM0.44 million in the corresponding quarter ended 31 December 2020. The increase in profit before tax of RM2.75 million or 625.28% in current quarter was mainly due to higher revenue recorded as mentioned above as well as the realised gain on disposal of quoted investments.

Cumulative quarter (12 months)

	Cumulativ	e Quarter		
	(Unaudited) (Audited)			
	31 December	31 December	Ol-	
	2021	2020		inges
	RM'000	RM'000	RM'000	Percentage
Revenue	75,259	68,127	7,132	10.47%
Operating profit	75	3,874	(3,799)	(98.06%)
Profit before interest and tax	2,812	5,007	(2,195)	(43.84%)
Profit before tax	2,256	4,613	(2,357)	(51.09%)
Profit after tax	98	3,316	(3,218)	(97.04%)
(Loss)/Profit attributable to owners of the Company	(1,176)	2,658	(3,834)	(144.24%)

For the cumulative twelve (12) months of the year ended 31 December 2021, the Group's revenue had increased by RM7.13 million or 10.47% to RM75.26 million as compared to RM68.13 million in the corresponding cumulated quarter ended 31 December 2020. As disclosed in Note A7, the higher revenue was mainly due to the increase in revenue contribution from healthcare products business segment, health food and beverage business segment and laundry services business segment.

The healthcare products business segment recorded a sharp rise in revenue by RM14.64 million or 119.70% to RM26.87 million in the current cumulative quarter ended 31 December 2021, compared to RM12.23 million in the corresponding cumulative quarter ended 31 December 2020. The increase in revenue was mainly due to new sales generated from virus attenuation devices and higher demand for other healthcare products as consumers became more healthconscious under the COVID-19 climate.

The Group's new health food and beverage business segment also contributed RM3.26 million revenue in the current cumulative quarter ended 31 December 2021, indicates good demand from customers for consumption of our products.

The Group's laundry services business segment contributed RM0.74 million revenue in the current cumulative quarter, an increase of 4.79% or RM0.03 million compared to RM0.71 million in the corresponding cumulative quarter ended 31 December 2020. The improvement was mainly due to good demand from customers for use of our services.

The commercial laundry equipment business segment recorded a decrease in revenue by RM6.21 million or 25.02% to RM18.60 million as compared to RM24.81 million in the corresponding cumulative quarter ended 31 December 2020. The lower revenue was mainly due to conservative approach adopted by potential customers (more caution in their investment direction) during current economic challenging time which resulted in lower sales in current cumulative quarter.

Registration No: 201501009903 (1135238-U)

(Incorporated in Malaysia)

INTERIM FINANCIAL REPORT FOR THE FOURTH (4th) QUARTER ENDED 31 DECEMBER 2021

B1. Review of performance (continued)

Cumulative quarter (12 months) (continued)

The medical devices business segment registered a revenue of RM25.77 million in the current cumulative quarter, a decrease of RM4.68 million or 15.36% compared to RM30.45 million in the corresponding cumulative quarter ended 31 December 2020. The lower revenue was primarily due to lower billing to a number of its clients as some of the hospitals have either postponed or temporary put on hold their expansion plans during current economic challenging time.

For the cumulative quarter under review, the Group registered a profit before tax of RM2.26 million as compared to profit before tax of RM4.61 million in the correspondence cumulative quarter ended 31 December 2020. The decrease in profit before tax of RM2.36 million or 51.09% in current cumulative quarter was mainly due to the higher professional fees incurred for Covid-19 test kits and virus attenuation devices in healthcare products business segment and marketing expenses for the Group's Covid-19 test kits sub-business segment and on-demand laundry services sub-business segment.

B2. Comparison with immediate preceding quarter's results

	Individua			
	(Unaudited) (Unaudited) 31 December 30 September			
	2021	2021	Changes	
	RM'000	RM'000	RM'000	Percentage
Revenue	25,553	16,965	8,588	50.62%
Operating profit/(loss)	130	(1,404)	1,534	109.26%
Profit before interest and tax	3,322	3,244	78	2.40%
Profit before tax	3,184	3,044	140	4.60%
Profit after tax	2,482	2,342	140	5.98%
Profit attributable to owners of the Company	2,611	1,509	1,102	73.03%

For the current quarter ended 31 December 2021, the Group recorded a revenue of RM25.55 million and profit before tax of RM3.18 million as compared to a revenue of RM16.97 million and profit before tax of RM3.04 million in the immediate preceding quarter ended 30 September 2021.

The Group's healthcare products business segment registered a higher revenue by RM4.10 million or 58.24% to RM11.14 million in the current quarter as compared to RM7.04 million in the immediate preceding quarter, mainly due to new sales generated from virus attenuation devices and higher demand for other healthcare products as consumers became more healthconscious under the COVID-19 climate.

For the current quarter, our medical devices business segment recorded an increase in revenue by RM2.23 million or 39.15% to RM7.93 million as compared to RM5.70 million in the immediate preceding quarter ended 30 September 2021. The increase in revenue contribution from the medical devices business segment was mainly attributable to more orders secured from its customers for medical imaging equipment in current quarter.

For the commercial laundry equipment business segment, its revenue increased by RM1.58 million or 50.79% in the current quarter as compared to the immediate preceding quarter. The higher revenue was mainly due to more sales orders secured as a result of effectiveness of our promotion package; advertisement platform and webinar conducted in current quarter.

Registration No: 201501009903 (1135238-U)

(Incorporated in Malaysia)

INTERIM FINANCIAL REPORT FOR THE FOURTH (4th) QUARTER ENDED 31 DECEMBER 2021

B2. Comparison with immediate preceding quarter's results (continued)

The Group's health food and beverage business segment increased in revenue by RM0.55 million or 55.70%. It contributed RM1.53 million revenue in the current quarter compared to RM0.98 million in the immediate preceding quarter. This indicates good demand from customers for consumption of our products, as well as effectiveness of our marketing strategy.

The Group's laundry services business segment increased in revenue by RM0.13 million or 97.73%. It contributed RM0.26 million revenue in the current quarter compared to RM0.13 million in the immediate preceding quarter. The increase was mainly due to good demand from customers for use of our laundry services in view of lesser COVID-19 cases in the current quarter.

The Group recorded profit before tax of RM3.18 million in current quarter as compared to profit before tax of RM3.04 million in the immediate preceding quarter. The increase in profit before tax of RM0.14 million or 4.60% in current quarter was mainly due to the higher revenue recorded as mentioned above.

Registration No: 201501009903 (1135238-U)

(Incorporated in Malaysia)

INTERIM FINANCIAL REPORT FOR THE FOURTH (4th) QUARTER ENDED 31 DECEMBER 2021

B3. Prospects

In tandem with the Group's focus to enhance its revenue growth, optimise margin, business and operation support functions as well as to increase shareholders' value, BCM intends to achieve its objectives through the following strategies:

(i) Continuous introduction of our new portfolio of products and services.

In 2022, BCM will continue to introduce few suitable new medical devices (including but not limited to the high-end and cost effective solutions medical devices) and healthcare products that have strong demand or traction in the market as well as intends to introduce advanced health station which can be placed in pharmacies, hospital and corporate places to attract end-users to experience our core healthcare brand's Bluetooth products before they buy a device and become our core healthcare brand's health style application members, to expand our portfolio of products and brands to enhance the Group's future performance.

The Group will keep increasingly focusing on consumable proprietary products as well as cash-in spare parts. Besides that, BCM has leverage on the enhancement business model by renting out Ripple Mattress that provides recurring income, and also intends to introduce stand-alone clinical application software and workstation to meet unique visualization needs in future.

(ii) <u>Pursue active business expansion via organic and inorganic growth.</u>

BCM aggressively expands its product and service offerings via organic and inorganic growth to create additional income streams in future.

This is in line with the Group's business direction and strategy which is continuously looking for opportunities to further expand its business to ultimately improve its financial performance and enhance shareholders' value.

Registration No: 201501009903 (1135238-U)

(Incorporated in Malaysia)

INTERIM FINANCIAL REPORT FOR THE FOURTH (4th) QUARTER ENDED 31 DECEMBER 2021

B3. Prospects (continued)

(iii) <u>Broaden our client base by attracting new customers and enhancing the relationship with</u> our existing customers.

BCM is targeting to add more new prospective hospitals and medical centres into its portfolio of clients, especially through the supply of big-ticket medical equipment. This will support the Group's continuous effort to widen its product line and after-sales services.

The Group's healthcare products segment also targeting to attract more new customers under various categories such as chain pharmacy; chain independent pharmacy; independent pharmacy; hospital; clinic; medical dealers; corporate; non-medical retail shop; E-commerce company; online and etc., to boost up its performance in 2022.

Our management and marketing team are also working proactively to secure new customers to expand our current customer base via various promotion packages; up-to-date advertisement channels and data-driven digital marketing activities. We are keeping improvement to provide continuous sales support to our existing customer by rendering value-added training as well as providing suggestion and recommendation on any suitable device/machine, suitable upgrade, replacement and service packages to our existing customer as an initiative to secure potential sales order in 2022.

(iv) Strengthening of self-service launderette and commercial laundry equipment business.

The Group's commercial laundry equipment business segment is targeting to penetrate commercial coin laundry equipment market into a Southeast Asia country in future, to benefit from another growth market which could spell opportunities for BCM in future.

In 2022, besides to keep increasing to conduct laundry opportunity sharing webinar to enhance its revenue growth, the Group also plans to provide one stop solution program for customer to start up laundromat business by adopting mutual benefits concept. The Group also plans to resume business seminar in hotels to public at large to promote its business.

Online platform to sell laundry equipment spare parts and providing maintenance services, also another digital one-stop solution platform planned to be implemented by the Group in future to boost up its future revenue.

The Group currently operates 12 self-service laundrette outlets. In addition, the Group intends to set up another 5 new self-service laundrette outlets in future, to improve our capability to meet customers' demand and to enhance the Group's revenue.

The Group has ventured into the provision of on-demand laundry services via its wholly-owned subsidiary company namely BCM Laundry Services Sdn. Bhd.. This is aimed at capitalising on the increase in demand for various online delivery services, including on-demand laundry services, following a behavioural shift in consumers opting for goods and services to be delivered to their doorstep to avoid going out in order to minimise exposure to COVID-19. Premised on the above, the Group is optimistic the outlook and prospects of its laundry services business segment in near future.

Registration No: 201501009903 (1135238-U)

(Incorporated in Malaysia)

INTERIM FINANCIAL REPORT FOR THE FOURTH (4th) QUARTER ENDED 31 DECEMBER 2021

B3. Prospects (continued)

(v)Penetrate into virus attenuation or reduction devices business

BC Medicare Sdn Bhd, a wholly-owned subsidiary company of BCM, had on 23 December 2021 entered into a Manufacturing Agreement ("the Agreement") with rLoop Limited ("rLoop"), a Hong Kong corporation have received a letter of offer from Euro-China Technology Achievement Transformation (Tianjin) Co Ltd. ("EC Tech"), a company incorporated in China to purchase 100,000 units of virus attenuation devices with a total sale of US\$200 million (RM845 million), to manufacture, test, configure, assemble, package and/or ship the virus attenuation devices using photon mediated electrons and emitters under rLoop's own brand name of "rGuard-rLoop Virus Attenuation Device" ("Product"). A separate Original Equipment Manufacturer ("OEM") manufacturing agreement between rLoop and BCM is underway. BCM will also be responsible for providing training to EC Tech on the functions and operations of the Products.

The Products can disable the coronavirus in enclosed spaces with up to 99.9% efficacy, enabling users to get back to normal and serve the people in a safe environment.

The Agreement enables the Company to penetrate into virus attenuation devices business that might yield attractive return to the Group. The prospects in respect of the proposed engagement shall deem to be strong and convincible with exponentially growth of the demand reckons amidst the expectation of herd immunity post inoculation program across the world.

(vi) Strengthening of health food and beverage business segment

The Group is targeting to add more new customers; accelerate the mastery of online channels; listing products via various hypermarkets and distribution centres; conducting attractive marketing campaigns to promote products; enhance marketing strategy and looking for new products with higher profit margins in order to enhance the health food and beverage business segment's income stream in 2022.

Registration No: 201501009903 (1135238-U)

(Incorporated in Malaysia)

INTERIM FINANCIAL REPORT FOR THE FOURTH (4th) QUARTER ENDED 31 DECEMBER 2021

B3. Prospects (continued)

Effect of outbreak of coronavirus pandemic ("COVID-19")

The financial impact of the COVID-19 outbreak to the Group cannot be reasonably estimated due to the inherent unpredictable nature and rapid development relating to COVID-19, the extent of the impact depends on the ongoing precautionary measures introduced by each country to address this pandemic and the durations of the pandemic. However, the Directors of the Company have continuously monitoring the local and global development of the outbreak of COVID-19 and also work closely with the trade partners and suppliers to ensure minimal disruption.

Looking ahead, we remain steadfast in our commitment to protect the health and safety of our teams around the world as we navigate these uncertain times. We are highly focused on the execution of our strategic initiatives and are taking decisive actions to mitigate the challenges created by the COVID-19 global pandemic on the Group's performance in 2022.

B4. Profit forecast or profit guarantee

The Group does not have any profit forecast or profit guarantee for the current quarter under review in any public documents.

B5. Taxation

	Individual Quarter Ended (Unaudited) (Unaudited) 31 December 31 December 2021 2020 RM'000 RM'000		Cumulative Q (Unaudited) 31 December 2021 RM'000	Quarter Ended (Audited) 31 December 2020 RM'000
Income tax expense: -Current financial period -Under/(Over) provision in	632	377	2,077	1,545
prior years	2	(143)	2	(142)
	634	234	2,079	1,403
Deferred tax expense/(income)	-	(00)		(24)
-Current financial period -Under provision of deferred tax income in	68	(92)	79	(21)
prior years		-	-	(85)
Total tax expense	702	142	2,158	1,297

The Group's effective tax rate for the current quarter and financial period-to-date is higher than the statutory tax rate mainly due to certain non-tax deductible expenses.

Registration No: 201501009903 (1135238-U)

(Incorporated in Malaysia)

INTERIM FINANCIAL REPORT FOR THE FOURTH (4th) QUARTER ENDED 31 DECEMBER 2021

B6. Status of corporate proposals

Status of utilisation of proceeds raised from corporate proposals

 a) Proposed special issue of up to 60,197,000 new ordinary shares in the Company to bumiputera investors to be identified and/or approved by MITI ("Proposed Special Issue")

On 19 June 2020, the Company proposed to undertake the Special Issue and it has been completed on 11 December 2020 following the listing of and quotation for 60,197,000 new ordinary shares at RM0.26 per share on the ACE Market of Bursa Malaysia Securities Berhad.

This Special Issue is undertaken to comply with the Bumiputera Equity Conditions (requirement by the Securities Commission Malaysia for the Company to meet a minimum 12.50% Bumiputera shareholdings).

The gross proceeds raised from the Special Issue Shares amounting to RM15.65 million was partially utilised in the following manner as at 17 February 2022: -

Utilisation of proceeds	Intended timeframe for utilisation from 11 December 2020	Actual proceeds raised (RM'000)	Actual utilisation up to 17/2/2022 (RM'000)	Balance available for utilisation (RM'000)
(i) Purchase of new devices and equipment	Within 24 months	9,750	(8,320)	1,430
(ii) Working capital	Within 6 months	5,439	(5,439)	-
(iii) Estimated expenses for the Special Issue	Within 1 month	462	(462)	-
Total		15,651	(14,221)	1,430

There was no deviation between the approved utilisation amount and actual utilised amount.

Registration No: 201501009903 (1135238-U)

(Incorporated in Malaysia)

INTERIM FINANCIAL REPORT FOR THE FOURTH (4th) QUARTER ENDED 31 DECEMBER 2021

B6. Status of corporate proposals (continued)

Status of utilisation of proceeds raised from corporate proposals (continued)

b) Proposed private placement of up to 144,434,000 new ordinary shares in the Company, representing 30% of the existing total number of issued shares of the Company, to independent third-party investor(s). ("Proposed Private Placement")

On 27 January 2021, the Company proposed to undertake a private placement of up to 144,434,000 new ordinary shares in the Company, representing 30% of the existing total number of issued Shares, to independent third-party investor(s) to be identified later and at an issue price to be determined later.

The rationale for this Proposal is enable the Group to raise fund to fund its business expansion into the trading of COVID-19 test kits.

On 5 February 2021, Bursa Malaysia Securities Berhad ("Bursa Securities") had, vide its letter dated 5 February 2021, approved the listing and quotation of up to 144,434,000 Placement Shares to be issued pursuant to the Proposed Private Placement.

On 4 March 2021, the Proposed Private Placement has been approved by shareholders of the Company at an Extraordinary General Meeting.

On 12 March 2021 and 15 March 2021, 41,252,181 and 39,545,455 Placement Shares, being the first tranche of Placement Shares for the Private Placement have been listed on the ACE Market of Bursa Securities respectively at RM0.220 per share.

On 25 March 2021, 63,636,000 Placement Shares, being the second and final tranche of Placement Shares for the Private Placement has been listed on the ACE Market of Bursa Securities, at RM0.225 per share.

On 25 March 2021, the Company has decided not to place out the remaining 364 Placement Shares out of the 144,434,000 Placement Shares. As such, the Private Placement is deemed completed.

The gross proceeds raised from the Private Placement amounting to RM32.09 million have

been partially utilised in the following manner as at 17 February 2022: -

Utilisation of proceeds	Intended timeframe for utilisation from 25 March 2021	Actual proceeds raised (RM'000)	Actual utilisation up to 17/2/2022 (RM'000)	Balance available for utilisation (RM'000)
(i) Business expansion into the trading of COVID-19 test kits	Within 24 months	31,689	(15,517)	16,172
(iii) Expenses for the Private Placement	Immediate	405	(405)	-
Total		32,094	(15,922)	16,172

There was no deviation between the approved utilisation amount and actual utilised amount.

Registration No: 201501009903 (1135238-U)

(Incorporated in Malaysia)

INTERIM FINANCIAL REPORT FOR THE FOURTH (4th) QUARTER ENDED 31 DECEMBER 2021

B6. Status of corporate proposals (continued)

Status of utilisation of proceeds raised from corporate proposals (continued)

c) Proposed Rights Issue with Warrants

On 5 May 2021, the Company proposed to undertake a renounceable rights issue of up to 1,220,467,629 new ordinary shares in the Company ("Rights Shares") together with up to 1,017,056,357 free detachable warrants in the Company ("Warrants") on the basis of 6 Rights Shares together with 5 free Warrants for every 4 existing Shares held by the entitled shareholders of the Company ("Entitled Shareholders") ("Proposed Rights Issue with Warrants").

The Proposed Rights Issue with Warrants will enable the Company to raise funds and channel them towards the expansion of business of providing on-demand laundry services.

Bursa Securities had, vide its letter dated 24 May 2021, approved the listing and quotation of Rights Shares and Warrants to be issued.

On 24 June 2021, the Proposed Rights Issue with Warrants has been approved by shareholders of the Company at an Extraordinary General Meeting.

On 8 July 2021, the Company has resolved to fix the issue price of the Rights Shares at RM0.08 per Rights Share and the exercise price of the Warrants at RM0.10 per Warrant.

On 30 August 2021, the Proposed Rights Issue with Warrants has been completed following the listing and quotation of 938,821,251 Rights Shares and 782,350,787 Warrants on the ACE Market of Bursa Securities.

The gross proceeds raised from the Rights Issue with Warrants amounting to RM75.11 million have been partially utilised in the following manner as at 17 February 2022: -

Utilisation of proceeds	Intended timeframe for utilisation from 30 August 2021	Actual proceeds raised (RM'000)	Actual utilisation up to 17/2/2022 (RM'000)	Balance available for utilisation (RM'000)
(i) Investment in the business of providing on-demand laundry services	Within 18 months	42,000	(40,301)	1,699
(ii) Working capital	Within 24 months	32,401	(360)	32,041
(iii) Estimated expenses for the Rights Issue with Warrants	Immediate	705	(705)	-
Total		75,106	(41,366)	33,740

There was no deviation between the approved utilisation amount and actual utilised amount.

Registration No: 201501009903 (1135238-U)

(Incorporated in Malaysia)

INTERIM FINANCIAL REPORT FOR THE FOURTH (4th) QUARTER ENDED 31 DECEMBER 2021

B7. Lease liabilities & bank borrowings

The Group's lease liabilities and bank borrowings were as follows: -

	As at 31 December 2021 (Unaudited)			
	Long term RM'000	Short term RM'000	Total RM'000	
Secured (i) Bank borrowings				
- Banker acceptance	-	1,927	1,927	
 Bank overdraft 	-	256	256	
- Term loans	6,729	1,966	8,695	
Sub-total	6,729	4,149	10,878	
(ii) Lease liabilities	1,513	1,082	2,595	
Grand total	8,242	5,231	13,473	

	As at 31 December 2020 (Audited)		
	Long term RM'000	Short term RM'000	Total RM'000
Secured (i) Bank borrowings			
 Banker acceptance 	-	1,252	1,252
 Trust receipts 	-	1,795	1,795
- Term loans	2,324	299	2,623
Sub-total	2,324	3,346	5,670
			_
(ii) Lease liabilities	1,882	1,036	2,918
Grand total	4,206	4,382	8,588

Notes:

- (1) All bank borrowings are denominated in Ringgit Malaysia and there were no foreign currency denomination bank borrowings.
- (2) All bank borrowings are secured and the Group do not have any unsecured bank borrowings.
- (3) The average effective interest rates per annum are as follows:

	Rates (%)
Banker acceptance	4.53
Trust receipts	6.14-6.92
Term loans	3.25-4.77
Lease liabilities	2.24-9.90

(4) There were no additional lease liabilities and bank borrowings during the current quarter.

Registration No: 201501009903 (1135238-U)

(Incorporated in Malaysia)

INTERIM FINANCIAL REPORT FOR THE FOURTH (4th) QUARTER ENDED 31 DECEMBER 2021

B8. Changes in material litigation

As at 17 February 2022 (the latest practicable date which is not earlier than 7 days from the date of issue of this interim financial report), the BCM Group is not involved in any litigations or arbitrations, either as a defendant or plaintiff, which has a material effect on the financial position of the Group, and the Board is not aware of any proceedings pending or of any fact likely to give rise to any proceedings.

B9. Dividend Proposed/Declared

There was no dividend proposed/declared for the current financial period under review.

Registration No: 201501009903 (1135238-U)

(Incorporated in Malaysia)

INTERIM FINANCIAL REPORT FOR THE FOURTH (4th) QUARTER ENDED 31 DECEMBER 2021

B10. Earnings/(Loss) per share

The basic/diluted earnings/(loss) per share is calculated based on the Group's profit/(loss) attributable to owners of the Company divided by the weighted average number of ordinary shares as follows:

	Individual Quarter		Cumulative Quarter	
	(Unaudited) 31 December 2021	(Unaudited) 31 December 2020	(Unaudited) 31 December 2021	(Audited) 31 December 2020
Profit/(Loss) attributable to owners of the Company (RM'000)	2,611	285	(1,176)	2,658
Weighted average number of issuance shares ('000)	1,564,702	434,991	914,532	424,704
Basic ⁽¹⁾ /Diluted ⁽²⁾ earnings/(loss) per share (sen)	0.17	0.07	(0.13)	0.63

Notes:

- (1) Basic earnings/(loss) per share for the current quarter and cumulative quarter is calculated based on the net profit/(loss) attributable to owners of the Company divided by the weighted average number of ordinary shares for the current quarter and cumulative quarter respectively.
- (2) Diluted earnings/(loss) per share of the Company for the current quarter and cumulative quarter is equivalent to the basic earnings/(loss) per share as the effects on the assumed exercise of the share options under warrants is anti-dilutive.

B11. Financial Instruments

(a) Derivatives

There were no outstanding derivatives as at 31 December 2021.

(b) Gain/(Loss) arising from fair value changes in financial liabilities

There were no gain/ (loss) arising from fair value changes in financial liabilities during the current guarter and year ended 31 December 2021.

Registration No: 201501009903 (1135238-U)

(Incorporated in Malaysia)

INTERIM FINANCIAL REPORT FOR THE FOURTH (4th) QUARTER ENDED 31 DECEMBER 2021

B12. Disclosure on selected expense/ (income) items as required by the Listing Requirements

	(Unaudited) Current quarter ended 31 December 2021 RM'000	(Unaudited) Cumulative quarter ended 31 December 2021 RM'000
Profit before taxation is arrived after charging/(crediting)		
Depreciation of property, plant and equipment	314	1,147
Depreciation of right-of-use assets	357	1,537
Depreciation of investment properties:		
-Current	38	66
-Overstated in prior years	(17)	(94)
Fair value adjustment on investment property	103	-
Gain on disposal of property, plant and equipment	-	-
Gain on disposal of right-of-use assets	(146)	(149)
Gain/(Loss) on derivatives	-	-
Income from rent concession	-	(5)
Inventory written down	-	-
Interest expenses	138	556
Interest income	(264)	(756)
Gain on disposal of quoted investments - realised	(6,594)	(694)
Unrealised loss/(gain) on disposal of quoted investments	4,172	(81)
Impairment loss on financial instruments	219	219
Property, plant and equipment written off	95	417
Reversal of impairment loss on financial instruments	(314)	(314)
Unrealised gain on foreign exchange differences	(256)	(206)
Realised loss on foreign exchange differences	55	250

Registration No: 201501009903 (1135238-U)

(Incorporated in Malaysia)

INTERIM FINANCIAL REPORT FOR THE FOURTH (4th) QUARTER ENDED 31 DECEMBER 2021

B13. Approvals obtained for registration of medical devices from Medical Device Authority of Malaysia for registration

In relation to the requirements on registration of medical devices, Section 5 (1) of the Medical Devices Act, 2012 requires, amongst others, that all medical products classified as medical devices under the Medical Devices Act, 2012 and Medical Devices Regulation, 2012 shall be registered before they can be imported, exported or placed in the market. As at 17 February 2022, the Group has submitted a total of two hundred and sixty five (265) online applications to register medical devices that the Group are currently distributing and which are classified as medical devices pursuant to the Medical Devices Act, 2012 and Medical Devices Regulation, 2012 with the Medical Device Authority ("MDA").

As at 17 February 2022, out of the total applications submitted by the Group, there were: -

- (i) One hundred and seventy one (171) applications that have been successfully approved by MDA and was in use by the Group;
- (ii) One (1) application is still under consideration by the MDA; and
- (iii) Ninety three (93) applications shall either be dropped by the Group due to discontinuance of distribution of certain types of medical devices, or cancellation by the MDA mainly due to misclassification of the particular of certain medical devices under the Medical Devices Act, 2012.

BY ORDER OF THE BOARD 24 February 2022